Brief: Biofrontera Announces Data Base Locks For Two Clinical Studies Supporting Key Data And Regulatory Milestones
08/01/2026 14:40
Jan 8 (Reuters) - Biofrontera Inc BFRI.O: BIOFRONTERA INC. ANNOUNCES DATA BASE LOCKS FOR TWO CLINICAL STUDIES SUPPORTING KEY DATA AND REGULATORY MILESTONES BIOFRONTERA INC - PLANS TO SUBMIT SNDA TO FDA IN SUMMER 2026 BIOFRONTERA INC - PHASE 2 ACNE STUDY RESULTS TO FDA IN EARLY Q3 2026 Source text: ID:nGNX2CbdbF Further company coverage: BFRI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Biofrontera
See all newsBrief: Biofrontera Submits Supplemental New Drug Application To FDA To Expand Ameluz® Red Light Pdt To Actinic Keratoses On The Full Body
Biofrontera Inc reports results for the quarter ended June 30 - Earnings Summary
Biofrontera Q2 revenue rises on higher volume, pricing
Biofrontera Inc expected to post a loss of 10 cents a share - Earnings Preview
Biofrontera Q1 revenue rises on higher Ameluz sales